Cytokinetics, Incorporated 7,291,667 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • July 17th, 2020 • Cytokinetics Inc • Pharmaceutical preparations • New York
Cytokinetics, Incorporated, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 7,291,667 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 1,093,750 additional shares (the “Optional Securities”) of common stock, par value $0.001 (“Stock”), of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Securities”).
